Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada Sees Face-Off Over Higher-Strength Adalimumab

Jamp And Alvotech Go Head-To-Head With Celltrion On 100mg/ml Biosimilar Humira

Executive Summary

Hot on the heels of rival Celltrion, Jamp and partner Alvotech have now launched their own higher-strength adalimumab biosimilar in Canada, setting up a showdown between their Simlandi version and Celltrion’s Yuflyma.

You may also be interested in...



Sandoz Lines Up Higher-Strength Adalimumab In Europe

Sandoz is looking to enter the European market for high-concentration adalimumab after announcing EMA acceptance of its filing for a 100mg/ml version of its Hyrimoz biosimilar. Celltrion and Stada/Alvotech already have higher-strength rivals to Humira available in Europe.

Stada And Alvotech Launch Higher-Strength Adalimumab In Europe

Stada and Alvotech have announced the launch of the Hukyndra higher-strength adalimumab biosimilar rival to Humira in selected European countries, with a wider roll-out to follow in the coming months.

Settlement Gives Celltrion Date For US Higher-Strength Humira Biosimilar

Celltrion has secured a US launch date for its higher-strength adalimumab biosimilar, Yuflyma, through a settlement with AbbVie. However, the company will face a number of other Humira rivals in 2023.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel